![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.50 | 0.34% | 1,600.50 | 1,600.00 | 1,601.00 | 1,612.50 | 1,597.00 | 1,600.50 | 548,559 | 10:55:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.46 | 66.33B |
Date | Subject | Author | Discuss |
---|---|---|---|
30/7/2020 11:24 | In five years this has barely spent any time above a price of 1600, it is really just back to its usual pattern, it’s not going to 20 quid, dream on, 1400 a lot more likely looking at every graph available, the split unlikely to be value enhancing becos of the debt it will be loaded with. | ![]() porsche1945 | |
30/7/2020 10:03 | Even in a "recession", there's always a need for essential medicines and vaccines, and GSK has got a large market for them. Also a pretty impressive pipeline for the future. | tradermichael | |
30/7/2020 08:56 | Dividend is not safe. We are just starting the deepest recession in history and revenue is likely to come under severe pressure. | ![]() zicopele | |
30/7/2020 08:04 | Nearly every other sector losing money, banks, airlines, retail, etc. Safe 5.12% dividend paid every 13 weeks, that will do me. | ![]() montyhedge | |
29/7/2020 19:46 | This is the key paragraph: 'Pipeline highlights -- Continued strengthening of the biopharma pipeline which now contains 35 medicines and 15 vaccines; over 75% of pipeline assets are focused on immunology...' So you either believe that pipeline will deliver, or not. Delivery has to be a couple of class leading medications to move the needle. If you look at their recent oncology approval, it was approved for use when four other options had failed, in other words an absolute last resort treatment. Many cancer patients may not even live to that stage. | ![]() essentialinvestor | |
29/7/2020 18:22 | Very disappointing share price action today. I have not had a chance to listen to the call yet, but reviews from posters here appear mixed. Oh well. | ![]() lovewinshatelosses | |
29/7/2020 18:12 | Net negative, large USD earnings exchanged into GBP. Cable nearing 1.30. | ![]() essentialinvestor | |
29/7/2020 18:07 | They say currency fluctuations, is a weak dollar against the pound, good for GSK or bad? | ![]() montyhedge | |
29/7/2020 18:05 | Just seen Sanofi boss on Sky, it's looking good, I reckon GSK/Sanofi will be the winners, catch the interview on Sky business section.Your be impressed. | ![]() montyhedge | |
29/7/2020 17:57 | GlaxoSmithKline 2Q Net Profit Boosted by Horlicks Sale ProceedsSource: Dow Jones NewsBy Ian Walker GlaxoSmithKline PLC on Wednesday reported a market-beating net profit for the second quarter of the year after booking a profit on the sale of its Horlicks business and other consumer healthcare brands, and backed its full-year forecast.The British pharmaceutical giant made a net profit for the quarter ended June 30 of 2.26 billion pounds ($2.92 billion) compared with GBP964 million for the same period last year, and a consensus of GBP1.12 billion taken from FactSet and based on three analysts' forecasts.Adjusted earnings per share--a metric closely watched by analysts that strips out one-off items--fell 38% when accounting for currency effects, to 19.20 pence from 30.5 pence, missing analysts' expectations of 19.63 pence, taken from FactSet and based on nine forecasts.Sales fell to GBP7.62 billion from GBP7.81 billion, missing a consensus forecast of GBP7.69 billion provided by FactSet.Looking ahead, the FTSE 100-listed company reiterated that it expects adjusted EPS to decline by between 1% and 4% at constant rates in 2020.Glaxo has declared a dividend of 19 pence for the quarter and said it expects the payout to remain unchanged at 80 pence a share for the year.Earlier Wednesday Glaxo and French peer Sanofi S.A. said that they had reached an agreement with the U.K. government to supply up to 60 million doses of a Covid-19 vaccine, subject to final contractspud | spud | |
29/7/2020 17:39 | https://www.fool.co. | ![]() montyhedge | |
29/7/2020 17:18 | GSK down to number two by valuation in my portfolio tonight. Replaced by ECM. | ![]() philanderer | |
29/7/2020 16:59 | GlaxoSmithKline plc 2020 Q2 - Results - Earnings Call Presentation In case anyone interested. | ![]() geckotheglorious | |
29/7/2020 16:15 | What yield is Kodak ? | ![]() montyhedge | |
29/7/2020 15:49 | What you want is a 'proper' drug company...that award today seems to be KODK, yes really! Grant (not even, it's a loan!) to make generic drug starting materials from US government and has just gone up 2500 % in 2 days. Seems that in today's market anything is possible, however improbable. Normal drug making companies are just dull. ;-) edit It's like the .com boom on speed! $2.50 to quoting near $60 after 10 trading halts and now seems to be hurtling back to earth like a meteorite! | ![]() polaris | |
29/7/2020 15:37 | They just don’t have the drugs. That’s where the serious dosh is. Always better to buy growth over dividends. I cannot see with the debt how they don’t slash the dividend, covid disruption may give them perfect excuse. At some point will have to do it becos there is no growth, and the only point to hold these is the cash return, so where does the share price then go, down, same if they make more biotech acquisitions. Better to own this in a fund as too much stock specific risk. Ill stick to investing in the s and p, U.K. listed stuff is for shorting only these days. | ![]() porsche1945 | |
29/7/2020 15:29 | It's all rear view mirror stuff, 19p dividend. I thought future looks exciting. | ![]() montyhedge | |
29/7/2020 15:26 | Maybe just me then.Always struggle with future looking stuff - when Iain looks back at numbers you know it is factual and correct. Hal always discusses forward looking stuff(which is his job) so maybe I am a bit unfair. Annoying accent as well!!!!! | ![]() watfordhornet | |
29/7/2020 15:15 | I thought Hal was good. | ![]() montyhedge | |
29/7/2020 15:13 | Much appreciated. | ![]() essentialinvestor | |
29/7/2020 15:10 | Numbers all look gloomy. Not too much to be happy with although probably not too surprisingPipeline a bit more positive although a bit of leap of faith whether you believe it is as rosy as suggested. Numbers reported are actual vs a pipeline so difficult for a pipeline to compensate for poor actual numbersGuessing the trump news not helping which I guess is impacting the share price as much if not more.I like Emma and Iain MacKay. Less convinced by Hal | ![]() watfordhornet | |
29/7/2020 14:54 | Double whammy Trump is again dropping drugs prices | abdullla | |
29/7/2020 14:51 | Watford, if you could post a very quick take, it would be much appreciated. | ![]() essentialinvestor |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions